Articles From: ImmunoCellular Therapeutics Announces Change to Meeting Date for Annual Meeting of Stockholders to ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences


2014/3/11
LOS ANGELES , March 11, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
Sign-up for ImmunoCellular Therapeutics Announces Change to Meeting Date for Annual Meeting of Stockholders investment picks
2014/3/13
Conference Call Today at 5:00 pm ET LOS ANGELES , March 13, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
Sign-up for ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results investment picks
2014/1/9
Highlights Include ICT-107 Results to Date, Ongoing Data Analyses and Phase III Planning LOS ANGELES , Jan.
Sign-up for ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma investment picks
2014/1/13
LOS ANGELES , Jan.
Sign-up for ImmunoCellular Therapeutics Provides Update on 2014 Corporate Strategies and Milestones investment picks
2014/2/25
LOS ANGELES , Feb.
Sign-up for ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union investment picks
2014/3/3
LOS ANGELES , March 3, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
Sign-up for ImmunoCellular Therapeutics to Present at ROTH Conference on March 11th investment picks
2014/2/3
LOS ANGELES , Feb.
Sign-up for ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 10, 2014 investment picks
2014/3/4
LOS ANGELES , March 4, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
Sign-up for ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 13, 2014 investment picks
2014/2/14
Featured Talk Emphasizes Importance of Antigen-Specific Dendritic Cell Cancer Vaccines to Generate Powerful T-Cell Response LOS ANGELES , Feb.
Sign-up for ImmunoCellular Therapeutics' Founder and Chief Scientific Officer, John Yu, MD, Presents at "Targeting Cancer Stem Cells" Symposium investment picks
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the European Commission has granted marketing approval for Kadcyla (trastuzumab emtansine; ado-trastuzumab emtansine in the US) in the European Union (EU). This event triggers a $5 million milestone payment to ImmunoGen.
Sign-up for ImmunoGen, Inc. Announces Approval of Roche’s Kadcyla® in the European Union investment picks
2013/12/3
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming 55th ASH Annual Meeting and Exposition investment picks
2013/10/18
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2014 Financial Results investment picks
2014/1/24
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2014 Financial Results investment picks
2013/11/5
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, announced today the decision to stop the IMGN901 Phase II SCLC study, following the recommendation of the trial’s independent Data Monitoring Committee (DMC). ImmunoGen is in the process of updating study investigators and regulatory authorities.
Sign-up for ImmunoGen, Inc. Announces Discontinuation of IMGN901 Study in Small-Cell Lung Cancer (SCLC) investment picks
ImmunoGen, Inc. (Nasdaq: IMGN) , a biotechnology company that develops novel anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that Gregory D.
Sign-up for ImmunoGen, Inc. Announces Executive Change investment picks
2013/8/1
ImmunoGen, Inc. (Nasdaq: IMGN) , a biotechnology company that develops novel anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced that the Company’s IMGN289 Investigational New Drug (IND) application has been accepted by the US FDA and is now active.
Sign-up for ImmunoGen, Inc. Announces FDA Acceptance of IND for Company’s Novel EGFR-Targeting ADC, IMGN289 investment picks
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics, today announced that Novartis has licensed the exclusive right to use the Company's antibody-drug conjugate (ADC) technology to develop anticancer therapeutics to an undisclosed target.
Sign-up for ImmunoGen, Inc. Announces Fifth New License Agreement in 2013 investment picks
2014/4/8
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the first findings from Company research aimed at optimizing the dosing of its IMGN853 product candidate.
Sign-up for ImmunoGen, Inc. Announces First Clinical Findings with Refined Dosing Strategy for IMGN853 investment picks
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Novartis has licensed the exclusive right to use the Company's ADC technology to develop anticancer therapeutics to an undisclosed target.
Sign-up for ImmunoGen, Inc. Announces New License Agreement investment picks
2013/10/15
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Announces Presentations at Upcoming AACR-NCI-EORTC Anticancer Conference investment picks
2014/3/17
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentations scheduled to be made by Company scientists at the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-9, 2014 in San Diego, CA.
Sign-up for ImmunoGen, Inc. Announces Presentations by Company Scientists at Upcoming AACR Annual Meeting investment picks
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, announced the results from Roche’s TH3RESA Phase III trial being presented today at the European Cancer Congress (ECC) in Amsterdam (abstract #LBA15). The findings were accepted as late-breaking data and also included in the Congress’s official press program.
Sign-up for ImmunoGen, Inc. Announces Results from Kadcyla® Phase III Trial, TH3RESA, Being Presented Today at the European Cancer Congress investment picks
ImmunoGen, Inc. (Nasdaq: IMGN) today announced the presentation of interim data from the ongoing Phase I trial of Sanofi’s SAR566658 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting (abstract #A73) being held in Boston.
Sign-up for ImmunoGen, Inc. Announces SAR566658 Clinical Findings Reported at AACR-NCI-EORTC Conference investment picks
2013/9/4
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences investment picks
2014/2/6
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: The webcasts will be accessible live through the “Investor Information” section of the Company’s website, www.immunogen.com ; a replay will be available for approximately a week.
Sign-up for ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences investment picks
2014/2/27
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: ImmunoCellular Therapeutics Announces Change to Meeting Date for Annual Meeting of Stockholders to ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity